VBI Vaccines Cost of Revenue 2011-2026 | VBIV

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.

What is included in the cost of revenue

Cost Category	Examples
Production Costs	Materials, wages of production staff, depreciation of equipment
Service and Support	Customer service, user support, technical assistance
Delivery and Logistics	Packaging, delivery of goods to customers
Hosting and Infrastructure	Servers, cloud platforms (especially for IT and SaaS companies)
Content and Licenses	License purchases, production royalties (e.g., in streaming services)

Importance of the Metric

Helps to understand how costly the revenue-generating process is.
A high cost of revenue may indicate:
Poor cost control
Low operational efficiency
A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Annual Cost of Revenue VBI Vaccines

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	9.17 M	7.9 M	4.51 M	5.19 M	3.67 M	3.75 M	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
9.17 M	3.67 M	5.7 M

Quarterly Cost of Revenue VBI Vaccines

2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.11 M	2.06 M	2.58 M	-	1.98 M	2.35 M	1.18 M	-	801 K	1.07 M	1.41 M	-	1.33 M	1.36 M	1.28 M	-	1.5 M	2.58 M	1.08 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
2.58 M	801 K	1.64 M

Cost of Revenue of other stocks in the Biotechnology industry

Issuer	Cost of Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	32.2 M	-	2.43 %	$ 254 M	Germany
Biohaven Pharmaceutical Holding Company Ltd. BHVN	91.7 M	$ 9.83	2.5 %	$ 636 M	USA
BioNTech SE BNTX	2.91 B	$ 98.36	-4.92 %	$ 27.2 B	Germany
AgeX Therapeutics AGE	40 K	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	27.2 M	-	-	$ 866 M	China
Midatech Pharma plc MTP	926 K	-	-18.52 %	$ 27.3 M	Britain
Cerus Corporation CERS	33.4 M	$ 2.57	26.6 %	$ 490 M	USA
ACADIA Pharmaceuticals ACAD	81.8 M	$ 21.92	-2.38 %	$ 3.63 B	USA
Ayala Pharmaceuticals AYLA	602 K	-	-	$ 7.46 M	Israel
AstraZeneca PLC AZN	12.4 B	-	-	$ 96.9 B	Britain
Berkeley Lights BLI	24.8 M	-	-7.31 %	$ 87 M	USA
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Caladrius Biosciences CLBS	31.1 M	-	-16.75 %	$ 25.8 M	USA
Aeterna Zentaris AEZS	90 K	-	5.93 %	$ 314 M	Canada
Cardiff Oncology CRDF	597 K	$ 1.74	0.29 %	$ 116 M	USA
Deciphera Pharmaceuticals DCPH	3.73 M	-	-	$ 2.18 B	USA
AIkido Pharma AIKI	145 M	-	1.93 %	$ 17.4 M	USA
Dynavax Technologies Corporation DVAX	49.4 M	-	-	$ 2.02 B	USA
Edesa Biotech EDSA	17.6 K	$ 17.93	-1.86 %	$ 57.3 M	USA
Eiger BioPharmaceuticals EIGR	24 K	-	-9.21 %	$ 2.55 M	USA
CureVac N.V. CVAC	238 M	-	-	$ 867 M	Germany
Ampio Pharmaceuticals AMPE	369 K	-	-11.43 %	$ 502 K	USA
Evogene Ltd. EVGN	767 K	$ 0.78	-	$ 27.9 M	Israel